<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414502</url>
  </required_header>
  <id_info>
    <org_study_id>385-07</org_study_id>
    <nct_id>NCT03414502</nct_id>
  </id_info>
  <brief_title>Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response</brief_title>
  <official_title>Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 16-week, open-label study to identify factors that help predict clinical responses&#xD;
      to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a&#xD;
      starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If&#xD;
      a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the&#xD;
      study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is&#xD;
      determined to be necessary will be considered end of study. End of study data (week 16) as&#xD;
      well as study serum will be collected. (Serum only collected on those subjects who have&#xD;
      consented to the addendum Serum and DNA of this study). A portion of the blood collected at&#xD;
      baseline, week 8 and week 16 with the addendum portion of the study is for future research&#xD;
      and will be utilized attempting to look to detect the generation of superoxide radicals. The&#xD;
      radicals have been shown to be associated with inflammation and may correlate with the&#xD;
      progression of RA. If this is true, then treatment with RA should decrease the levels of&#xD;
      these radicals signaling response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to gather, in a prospective manner, information on patients with&#xD;
      rheumatoid arthritis and their response to DMARD therapy. Specific aims of this study are:&#xD;
&#xD;
      A. To evaluate the efficacy of DMARD therapy as defined by attaining ACR 50 response after 16&#xD;
      weeks of therapy.&#xD;
&#xD;
      B. To identify predictors of DMARD response in patients with RA.&#xD;
&#xD;
        -  Does the presence of certain genetic factors such as the shared epitope predict DMARD&#xD;
           response&#xD;
&#xD;
        -  Does the presence of serological factors (e.g. ccp (cyclic citrullinated peptide)&#xD;
           isotypes) predict DMARD response&#xD;
&#xD;
        -  Does evidence of co-morbid conditions (e.g. periodontal disease) predict DMARD response&#xD;
&#xD;
      A maximum of 400 RA patients will be consented for this protocol. Subject accrual for&#xD;
      protocol v1.0 included UNMC (University of Nebraska Medical Center) and the RAIN (Rheumatoid&#xD;
      Arthritis Investigational Network) sites. Subject accrual for protocol v2.0 will be derived&#xD;
      exclusively from UNMC. Investigators have examined the discriminatory characteristics of&#xD;
      several clinical and biologic parameters in predicting treatment response (at least 50%&#xD;
      improvement based on ACR criteria) in initial analyses involving 54 participants with early&#xD;
      RA treated with methotrexate monotherapy in past RAIN clinical trials. In the initial&#xD;
      analyses, factors showing discriminatory characteristics have included rheumatoid factor (RF)&#xD;
      isotypes (particularly IgA (Immunoglobulin A) and IgM (Immunoglobulin M), matrix&#xD;
      metalloproteinase (MMP)-3, HLA-DRB1 (human leukocyte antigen-DR isotope) shared epitope&#xD;
      (SE)-containing alleles, C-reactive protein, and interleukin (IL)-1. For instance, we have&#xD;
      found that subjects with low serum concentrations of RF-IgM (&lt; 27 IU/ml) are more likely to&#xD;
      be non-responders than those with higher (&gt; 27 IU/ml) serum concentrations (79% vs. 43%).&#xD;
&#xD;
      Males and females will participate in this protocol. As RA is approximately three times more&#xD;
      common in females, it is anticipated that a higher percentage of the study subjects will be&#xD;
      female. Subjects will be &gt; 19 years of age. This age range was chosen because the age of&#xD;
      majority in Nebraska is 19. RA diagnosed before the age of 19 may not have the same disease&#xD;
      characteristics as defined by the American College of Rheumatology (ACR) criterion for RA.&#xD;
      Pediatric subjects will not be enrolled in this study. Rheumatoid arthritis occurs in all&#xD;
      races. No enrollment restrictions have been based on race or ethnic origin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of DMARD therapy for Rheumatoid Arthritis as defined by attaining ACR 50 response after 16 weeks of therapy.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify predictors of DMARD response in patients with RA</measure>
    <time_frame>16 weeks</time_frame>
    <description>What are predictors of DMARD response in RA patients?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using ACR 50 composite measure, does the presence of certain genetic factors such as the shared epitope predict DMARD response</measure>
    <time_frame>16 weeks</time_frame>
    <description>After 16 weeks of treatment, what is the number of participants with genetic factors such as the shared epitope demonstrating a 50% improvement in the number of tender and swollen joints, and a 50% improvement in three of five criteria: patient global assessment, physician global assessment, functional ability measure (most often Health Assessment Questionnaire/HAQ), visual analog pain scale and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Using ACR 50 composite measure, does the presence of serological factors (e.g. CCP isotypes) predict DMARD response</measure>
    <time_frame>16 weeks</time_frame>
    <description>After 16 weeks of treatment, what is the number of participants with serological factors such as CCP isotypes demonstrating a 50% improvement in the number of tender and swollen joints, and a 50% improvement in three of five criteria: patient global assessment, physician global assessment, functional ability measure (most often Health Assessment Questionnaire/HAQ), visual analog pain scale and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Using ACR 50 composite measure, does evidence of co-morbid conditions (e.g. periodontal disease) predict DMARD response</measure>
    <time_frame>16 weeks</time_frame>
    <description>After 16 weeks of treatment, what is the number of participants with co-morbid conditions such as periodontal disease, demonstrating a 50% improvement in the number of tender and swollen joints, and a 50% improvement in three of five criteria: patient global assessment, physician global assessment, functional ability measure (most often Health Assessment Questionnaire/HAQ), visual analog pain scale and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive methotrexate therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive abatacept therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive adalimumab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive azathioprine therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Barcitinib Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive barcitinib therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive certolizumab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive etanercept therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive golimumab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxycholoroquine Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive hydroxychloroquine therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive infliximab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leflunomide Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive leflunomide therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive minocycline therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive rituximab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive sarilumab therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfasalazine Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive sulfasalazine therapy for RA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tofacitinib Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive tofacitinib therapy for RA treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.</description>
    <arm_group_label>Methotrexate Therapy</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Abatacept Therapy</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Adalimumab Therapy</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Azathioprine Therapy</arm_group_label>
    <other_name>Imuran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Barcitinib Therapy</arm_group_label>
    <other_name>Olimuant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Certolizumab Therapy</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Etanercept Therapy</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Golimumab Therapy</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Hydroxycholoroquine Therapy</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Infliximab Therapy</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Leflunomide Therapy</arm_group_label>
    <other_name>Arava</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Minocycline Therapy</arm_group_label>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Rituximab Therapy</arm_group_label>
    <other_name>Rituxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Sarilumab Therapy</arm_group_label>
    <other_name>Kevzara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Sulfasalazine Therapy</arm_group_label>
    <other_name>Azulfidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Starting dose which may be adjusted as needed at the discretion of the investigator</description>
    <arm_group_label>Tofacitinib Therapy</arm_group_label>
    <other_name>Xeljanz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Diag. with RA with 4 of 7 ACR criteria: 1) Morning stiffness for at least 1 hr. and at&#xD;
             least 6 wks 2) Swelling of 3 or more joints for at least 6 wks. 3) Swelling of wrist,&#xD;
             MCP, or proximal interphalangeal joints for 6 or more wks 4) Symmetric joint swelling.&#xD;
             5) Hand x-rays with erosions or bony decalcifications. 6) RA nodules 7) RF positive&#xD;
&#xD;
          -  &gt;19 yrs old at time of diagnosis of RA&#xD;
&#xD;
          -  Current active disease with at least1 swollen joint&#xD;
&#xD;
          -  Starting new DMARD medication(s) please circle: abatacept, adalimumab, azathioprine,&#xD;
             barcitinib, certolizumab, etanercept, golimumab, hydroxychloroquine, infliximab,&#xD;
             leflunomide, methotrexate, minocycline, rituximab, sarilumab, sulfasalazine,&#xD;
             tofacitinib&#xD;
&#xD;
          -  If on other DMARDS, must be on stable dose for â‰¥ 6 wks&#xD;
&#xD;
          -  If on glucocorticoids must be on stable dose for 2 wks (&lt; 10mg of Prednisone per day&#xD;
             or equivalent)&#xD;
&#xD;
          -  Able to adhere to study visit schedule: enrollment, 8 wks &amp; 16 wks (+/- 2 wks)&#xD;
&#xD;
          -  Hgb &gt; 9g/dl&#xD;
&#xD;
          -  WBC &gt; 3.5&#xD;
&#xD;
          -  Neutrophils &gt; 1.0&#xD;
&#xD;
          -  Platelets &gt;100&#xD;
&#xD;
          -  Creatinine &lt;1.6&#xD;
&#xD;
          -  AST or ALT not over 1.2 x upper limit&#xD;
&#xD;
          -  Albumin: up to 1.0 g/dL less than lower limit of normal&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Men and women of child bearing potential not willing to practice successful method of&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R O'Dell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherrie L Edwards, BSDH</last_name>
    <phone>402-559-8140</phone>
    <email>sherrie.edwards@unmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherrie L Edwards, BSDH</last_name>
      <phone>402-559-8140</phone>
      <email>sherrie.edwards@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cindy S Marr, LPN</last_name>
      <phone>402-559-4873</phone>
      <phone_ext>4025594873</phone_ext>
      <email>cmarr@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James R O'Dell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 2, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>James R. O'Dell, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>DMARD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Golimumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data remains stored at UNMC for approved investigators at this site only at this time</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

